logo
  

Rubius To Discontinue Clinical Trials Of RTX-240, RTX-224 - Quick Facts

Rubius Therapeutics, Inc. (RUBY) announced plans to restructure the company. The measures include: implementing a 75% reduction in force, primarily focused on clinical development, manufacturing and general and administrative; discontinuing ongoing phase 1 clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors; and exploring the sale of manufacturing facility in Smithfield, Rhode Island.

"We plan to focus on advancing a next generation red blood cell platform that utilizes cell conjugation to potentially improve upon the existing benefits of the RED PLATFORM, with the potential for greater efficacy and enhanced versatility, while maintaining our favorable tolerability profile," said Pablo Cagnoni, CEO of Rubius Therapeutics.

Shares of Rubius Therapeutics are down 22% in pre-market trade on Tuesday.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT